Unicycive Therapeutics corrects warrant expiration dates via 8-K/A amendment

Unicycive Therapeutics, Inc.

Filing corrects inadvertent clerical error in Expiration Date on Exhibits 4.2 and 4.3 (Amended Tranche B and C Warrants) from Original 8-K.
No other changes made to Original Filing; all terms of Exchange Agreement and Amended Certificate of Designation remain unchanged.
Original March 2024 event exchanged 43,649,000 Series A-2 Preferred shares for Series A-2 Prime Preferred and amended warrants with reduced share counts and revised exercise price of $1,000.
Corrected exhibits reflect accurate expiration dates; no impact on conversion prices or aggregate exercise amounts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.